Request for Proposals (RFP) Immunotherapy in Urothelial Carcinoma

Well-being, Health and Biomedical Discovery


Academic Unit: inquire with unit

Memorial Deadline: Thursday 7th, April 2022

External Deadline: Tuesday 12th, April 2022


Pfizer Global Medical Grants (GMG), and Merck KGaA, Darmstadt, Germany – Global Medical Education & Academic Organization Relations (Global MedEd & AOR) are collaborating to provide grant support for continuing professional education and patient education in the area of Immuno-Oncology. Immuno-Oncology is a priority for Merck KGaA, Darmstadt, Germany and Pfizer Inc, and for the Global Strategic Alliance among our organizations.

This publicly posted Request for Proposal (RFP) provides details regarding a general area of interest, sets timelines for review and approval, and uses an internal company-alliance review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Our companies must not be involved in any aspect of project development, nor the conduct of the independent education program.

Date RFP Issued: February 15, 2022

Geographic Scope: Primary Geographies of Interest: Europe, Asia, Latin America; Secondary Geography: Global

Note: Applications for this RFP must have a European or Asian or Latin American focus. However if a program also has a broader global reach it would be welcomed and encouraged.

Clinical Area: Oncology – Genitourinary – Urothelial Carcinoma

Link to full RFP: Immunotherapy in Urothelial Carcinoma

Application Due Date: April 12, 2022

Specific Area of Interest: The intent of this RFP is to support independent education initiatives for healthcare professionals involved in the treatment of patients with locally-advanced or metastatic urothelial carcinoma (mUC), including oncologists, urologists, and specialty nurses. Patient education programs designed to specifically reach patients with urothelial carcinoma and their caregivers are also in scope for this RFP.

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: February 16, 2022